Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) issued its quarterly earnings data on Friday. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03), RTT News reports. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Trading Up 3.5 %

AMRX stock traded up $0.29 during trading hours on Friday, hitting $8.67. 2,898,126 shares of the stock were exchanged, compared to its average volume of 1,319,121. Amneal Pharmaceuticals has a 12 month low of $5.01 and a 12 month high of $9.48. The company has a 50-day simple moving average of $8.10 and a two-hundred day simple moving average of $8.32. The firm has a market capitalization of $2.69 billion, a P/E ratio of -12.75 and a beta of 1.10.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 62,590 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $8.01, for a total value of $501,345.90. Following the completion of the transaction, the director now owns 1,968,886 shares of the company’s stock, valued at $15,770,776.86. This represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 160,000 shares of company stock valued at $1,292,000 in the last three months. Corporate insiders own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on AMRX shares. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Piper Sandler upped their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Buy” and an average target price of $10.60.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.